Breaking News, Trials & Filings

Trials & Filings in Brief: Dec. 3, 2013

Astellas, Conatus, Durata, Lexicon, Medivation, Sanofi, Synageva

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase II
Lexicon completes IBS-d trial . . . read more

Phase III
Astellas, Medivation begin CRPC enrollment . . . read more

Sanofi posts U300 diabetes results . . . read more

Synageva meets enrollment target in LAL deficiency trial . . . read more

Filings
Astellas fungal treatment gets QIDP status . . . read more

Conatus gets Orphan status for liver treatment . . . read more

Durata submits MAA for dalbavancin . . . read more

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters